No Data
No Data
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Wave Life Sciences (WVE)
Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (Nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis With Cardiomyopathy
Express News | Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Nexiguran Ziclumeran (Nex-Z) for the Treatment of Transthyretin (Attr) Amyloidosis With Cardiomyopathy
Cathie Wood's ARK Investment Buys 205K Shares of Intellia Therapeutics Today
H.C. Wainwright Initiates Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $30